173 related articles for article (PubMed ID: 12848594)
1. Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Adis International Ltd
Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
3. Troxacitabine (Shire Pharmaceuticals).
Ecker G
Curr Opin Investig Drugs; 2002 Oct; 3(10):1533-8. PubMed ID: 12431032
[TBL] [Abstract][Full Text] [Related]
4. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
7. Troxacitabine in leukemia.
Swords R; Apostolidou E; Giles F
Hematology; 2006 Oct; 11(5):321-9. PubMed ID: 17607581
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine.
Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
[TBL] [Abstract][Full Text] [Related]
10. Troxacitabine in acute leukemia.
Swords R; Giles F
Hematology; 2007 Jun; 12(3):219-27. PubMed ID: 17558697
[TBL] [Abstract][Full Text] [Related]
11. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
12. [Troxacitabine].
Gourdeau H; Jolivet J
Bull Cancer; 2004 Mar; 91(3):213-8. PubMed ID: 15171046
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
[TBL] [Abstract][Full Text] [Related]
15. Troxacitabine-based therapy of refractory leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
[TBL] [Abstract][Full Text] [Related]
16. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.
Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J; McLntosh L; Seymour L
Lung; 2005; 183(4):265-72. PubMed ID: 16211462
[TBL] [Abstract][Full Text] [Related]
19. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
Lapointe R; Létourneau R; Steward W; Hawkins RE; Batist G; Vincent M; Whittom R; Eatock M; Jolivet J; Moore M
Ann Oncol; 2005 Feb; 16(2):289-93. PubMed ID: 15668286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]